Foghorn Therapeutics (FHTX) Debt Ratio (2019 - 2020)
Foghorn Therapeutics (FHTX) recorded quarterly Debt Ratio of 0.08 in Q4 2020, down 25.95% quarter-over-quarter from 0.1 in Q3 2020, and down 88.63% on a YoY basis from 0.68 in Q1 2020.
Foghorn Therapeutics (FHTX) Debt Ratio (2019 - 2020) Analysis & Trends
Foghorn Therapeutics' Debt Ratio history runs 2 years deep, the most recent figure standing at 0.08 for Q4 2020.
- In Q4 2020, Debt Ratio fell 88.63% year-over-year to 0.08; the TTM figure through Dec 2020 stood at 0.08 (down 88.63% YoY), while the FY2020 annual figure was 0.08, down 88.63% from the prior year.
- Debt Ratio was 0.08 for Q4 2020 at Foghorn Therapeutics, down from 0.1 in the prior quarter.
- In the past five years, Debt Ratio ranged from a high of 0.68 in Q4 2019 to a low of 0.08 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.18 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Foghorn Therapeutics | 282.33 Mn | 193.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 0.08 |
| Sep 30, 2020 | 0.10 |
| Dec 31, 2019 | 0.68 |